GSK3B and hepatocellular carcinoma: To further confirm the role of β-catenin as the downstream effector by which β-catenin mediates CSC functions, we treated UBE2T knockdown HCC cells with CHIR99021, a GSK3β inhibitor, at a dose of 1 μM to investigate whether the effects of UBE2T suppression were eliminated by the activation of β-catenin signaling.